orforglipron · Foundayo
Small molecule
Also known as LY3502970
Evidence outlook
Approved: Obesity
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
track record: Reliable signal
Also in development:Hypertension · Phase 3 · investigational in the USType 2 Diabetes · Phase 3 · investigational in the USAtherosclerotic Cardiovascular Disease · Phase 3 · investigational in the USOsteoarthritis · Phase 3 · investigational in the US
Also approved (1)
- Weight management in adults (BMI >=30, or 27-30 with a weight-related comorbidity) and glycaemic control in insufficiently controlled type 2 diabetes
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ACHIEVE-4 NCT05803421 · Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease ACHIEVE-4 was a randomized, open-label, event-driven Phase 3 trial. It assigned 2,749 adults with type 2 diabetes, obesity or overweight and established cardiovascular or chronic kidney disease to oral orforglipron or injected insulin glargine once daily. The primary endpoint was time to the first major cardiovascular event, and orforglipron had to be shown non-inferior to insulin glargine, with the upper limit of the 95% confidence interval for the hazard ratio below 1.8. Over a median of 2 years, events occurred in 4.2% of orforglipron patients and 5.0% of insulin glargine patients (hazard ratio 0.84, 95% CI 0.59 to 1.20), so non-inferiority was shown and the trial met its primary endpoint. The figures come from the peer-reviewed paper in The Lancet. Registry: NCT05803421 | 3 | Time to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4) [Myocardial Infarction (MI), Stroke, Hospitalization for Unstable Angina, or Cardiovascular (CV) Death] (Baseline to End of the Study (Approximate Maximum 104 Weeks)) 2026-03-16 | Primary endpoint, time to first MACE-4 (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalisation for unstable angina), non-inferiority with margin 1.8 on the upper 95% CI bound of the hazard ratio: 57/1358 (4.2%) orforglipron vs 67/1343 (5.0%) insulin glargine; HR 0.84 (95% CI 0.59 to 1.20; p<0.0001 for non-inferiority), met. | Partial signal | link ↗ |
View 5 more trials
ATTAIN-2 NCT05872620 · Obesity, Overweight, Type 2 Diabetes This large, randomized, double-blind, placebo-controlled trial met its primary endpoint: every orforglipron dose produced significantly greater weight loss than placebo (P<.001), with a clear dose-response and posted, per-arm statistical comparisons. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT05872620 | 3 | Mean Percent Change from Baseline in Body Weight (Baseline, Week 72) 2025-08-08 | Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001) | Reliable signal | link ↗ |
ATTAIN-MAINTAIN NCT06584916 · Obesity, Overweight The study randomized 376 participants to double-blind orforglipron or placebo and specified maintenance of body-weight reduction at week 52 as its primary clinical endpoint. Because no results or statistical comparison are posted, the outcome is currently unknown despite the randomized, blinded, placebo-controlled design. Registry: NCT06584916 | 3 | Percent Maintenance of Body Weight Reduction Achieved in SURMOUNT-5 (Week 52) 2025-11-21 | Results not posted; external-source review pending | Partial signal | link ↗ |
ATTAIN-1 NCT05869903 · Obesity This was a large randomized, double-blind, placebo-controlled trial with a clinical primary endpoint of percentage change in body weight, and the primary comparison was statistically significant in favor of orforglipron at all three doses. The record does not report a power or sample-size calculation, so the trial provides moderate rather than strong evidence despite its otherwise rigorous design. Registry: NCT05869903 | 3 | Percent Change From Baseline in Body Weight (Primary Treatment Period) (Baseline, Week 72) 2025-07-25 | Percent Change From Baseline in Body Weight (Primary Treatment Period) (Baseline, Week 72): Placebo -0.87 percent change (Standard Error 0.247) | 6 mg Orforglipron -7.82 percent change (Standard Error 0.302) | 12 mg Orforglipron -9.27 percent change (Standard Error 0.335) | 36 mg Orforglipron -12.35 percent change (Standard Error 0.364) | Partial signal | link ↗ |
NCT06948435 NCT06948435 · Obesity Registry: NCT06948435 | 3 | Change from Baseline in office Systolic Blood Pressure (SBP) (Baseline to Week 36) 2027-09 | — | not yet graded | link ↗ |
ATTAIN-OA PAIN NCT07153471 · Obesity Registry: NCT07153471 | 3 | Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score (Baseline, Week 72) 2028-04 | — | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (27)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (21)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (2)
What this study did
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 1 (1)
What this study did
Competitive landscape
Other GLP-1 receptor drugs
dulaglutide, Liraglutide (Saxenda), Liraglutide (Victoza), lixisenatide, Semaglutide (Ozempic) and 45 more. Compare all 51 GLP-1 receptor drugs
This mechanism is crowded: 50 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Type 2 Diabetes: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Orforglipron (Foundayo): this drug | Phase 3 | Small molecule | GLP-1 receptor | Partial signal | NCT05872620: Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001) NCT05803421: Primary endpoint, time to first MACE-4 (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalisation for unstable angina), non-inferiority with margin 1.8 on the upper 95% CI bound of the hazard ratio: 57/1358 (4.2%) orforglipron vs 67/1343 (5.0%) insulin glargine; HR 0.84 (95% CI 0.59 to 1.20; p<0.0001 for non-inferiority), met. | |
| Acarbose (Precose / Glucobay) | ApprovedUS marketing discontinued | Small molecule | Alpha-glucosidase | not yet graded | No reviewed efficacy summary in this indication | |
| Afrezza | Approved | Peptide | Insulin | Partial signal | NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed NCT01451398: Change in HbA1c from baseline to week 24: Technosphere Insulin + oral agents -0.82% (n=177) vs Technosphere powder (placebo) -0.42% (n=176); difference -0.40% (95% CI -0.57 to -0.23), p<0.0001 (CT.gov posted results). | |
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 | Partial signal | NCT02856113: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) missed NCT00968708: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) (From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).): Alogliptin 11.3% vs Placebo 11.8% | |
| Bexagliflozin (Brenzavvy) | Approved | Small molecule | SGLT2 | Reliable signal | NCT02769481: Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058) NCT03259789: Change From Baseline in HbA1c at Week 24 for Double-blind Group (Baseline to week 24): Double-blind Group: Bexagliflozin 20 mg -1.09 percentage of HbA1c (Standard Error 0.076) vs Double-blind Group: Placebo -0.56 percentage of HbA1c (Standard Error 0.075) | |
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | Partial signal | NCT03170518: Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002). NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction | |
| Colesevelam (Welchol) | Approved | Small molecule | Bile acid sequestrant | not yet graded | No reviewed efficacy summary in this indication | |
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | Partial signal | NCT01392677: Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02) NCT00984867: Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin -0.45 Percent (95% CI -0.55 to -0.35) vs Placebo 0.04 Percent (95% CI -0.06 to 0.14) | |
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | Reliable signal | NCT03495102: Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04) NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952 | |
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | Reliable signal | NCT01131676: Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1% NCT03429543: HbA1c change at week 26, empagliflozin pooled (10 mg and 25 mg) vs placebo: adjusted mean difference -0.84% (95% CI -1.50 to -0.19), p=0.0116. Treatment failure by week 26 in the small monotherapy cohort: 50.0% vs 60.0%, Fisher p=1.0 (CT.gov posted results). | |
| Ertugliflozin (Steglatro) | Approved | Small molecule | SGLT2 | Reliable signal | NCT01986881: Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years NCT01958671: Change in A1C at Week 26 versus placebo: ertugliflozin 5 mg −0.99 percentage points (95% CI −1.22 to −0.76; p<0.001); ertugliflozin 15 mg −1.16 percentage points (95% CI −1.39 to −0.93; p<0.001). | |
| Glimepiride (Amaryl) | ApprovedUS marketing discontinued | Small molecule | Sulfonylurea receptor (SUR1) | not yet graded | No reviewed efficacy summary in this indication | |
| Glipizide (Glucotrol) | ApprovedUS marketing discontinued | Small molecule | Sulfonylurea receptor (SUR1) | not yet graded | No reviewed efficacy summary in this indication | |
| Glyburide (DiaBeta) | Approved | Small molecule | Sulfonylurea receptor (SUR1) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Aspart (NovoLog) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Aspart (Fiasp) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Degludec (Tresiba) | Approved | Peptide | Insulin receptor (basal) | Partial signal | NCT00982644: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97) | |
| Insulin Detemir (Levemir) | ApprovedUS marketing discontinued | Peptide | Insulin receptor (basal) | Partial signal | NCT00856986: Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07) NCT00283751: HbA1c at 52 weeks: decreased from 8.6% to 7.2% with insulin detemir vs 8.6% to 7.1% with insulin glargine (no significant difference between arms); non-inferiority of detemir to glargine demonstrated. | |
| Insulin Efsitora Alfa (Onswik) | Approved | Protein / enzyme therapeutic | Insulin receptor (basal) | Partial signal | NCT05662332: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545) NCT05275400: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] (Baseline, Week 26): 500 U/mL - Insulin Efsitora -0.81 Percentage of HbA1c (Standard Error 0.0302) vs 100 U/mL - Insulin Degludec -0.72 Percentage of HbA1c (Standard Error 0.0424) | |
| Insulin Glargine (Lantus) | Approved | Peptide | Insulin receptor (basal) | Partial signal | No reviewed efficacy summary in this indication | |
| Insulin Glargine (Basaglar) | Approved | Peptide | Insulin receptor (basal) | Partial signal | NCT03338010: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062) NCT02302716: Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, 24 weeks): LY2963016 -1.25 Percentage of glycosylated hemoglobin (Standard Error 0.066) vs LANTUS® -1.22 Percentage of glycosylated hemoglobin (Standard Error 0.067) | |
| Insulin Glargine (Toujeo) | Approved | Peptide | Insulin receptor (basal) | Partial signal | NCT01499082: Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061) | |
| Insulin Glulisine (Apidra) | Approved | Peptide | Insulin receptor | Partial signal | NCT00135057: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly. | |
| Insulin Icodec (Awiqli) | Approved | Peptide | Insulin receptor (basal) | Partial signal | NCT06340854: Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89) NCT04760626: Change in Glycated Haemoglobin (HbA1c) (Baseline (week 0), week 52): Insulin Icodec -1.68 Percentage of HbA1c (Standard Error 0.09) vs Once Daily Basal Insulin Analogue -1.31 Percentage of HbA1c (Standard Error 0.12) | |
| Insulin Lispro (Humalog) | Approved | Peptide | Insulin receptor | Reliable signal | Featured results are non-efficacy only in this race | |
| Insulin Lispro (Lyumjev) | Approved | Peptide | Insulin receptor | Partial signal | NCT03952143: Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061) NCT03214380: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 (Baseline, Week 26): LY900014 -0.38 percentage of HbA1c (Standard Error 0.042) vs Insulin Lispro (Humalog) -0.43 percentage of HbA1c (Standard Error 0.042) | |
| Insulin NPH (Humulin N) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Linagliptin (Tradjenta) | Approved | Small molecule | DPP-4 | Partial signal | NCT01243424: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years NCT03429543: Primary HbA1c outcome at week 26: adjusted mean difference linagliptin versus placebo -0.34 percentage points (95% CI -0.99 to 0.30; p=0.2935). missed | |
| Liraglutide (Victoza) | Approved | Peptide | GLP-1 receptor | Reliable signal | NCT00318461: Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07) NCT00318422: HbA1c change from baseline at 26 weeks (added to glimepiride): liraglutide 1.2/1.8mg -1.1% (baseline 8.5%) vs placebo +0.2% (baseline 8.4%, P<0.0001) vs rosiglitazone -0.4% (baseline 8.4%, P<0.0001) | |
| Lixisenatide (Adlyxin / Lyxumia) | Approved | Peptide | GLP-1 receptor | Partial signal | NCT00707031: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054) NCT00688701: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 (Baseline, Week 12): Lixisenatide (Two-Step Titration) -0.73 percentage of hemoglobin (Standard Error 0.116) | Lixisenatide (One-Step Titration) -0.85 percentage of hemoglobin (Standard Error 0.119) | |
| Metformin (Glucophage) | ApprovedUS marketing discontinued | Small molecule | AMPK | Reliable signal | NCT00004992: Diabetes incidence: 11.0 (placebo) vs 7.8 (metformin) vs 4.8 (lifestyle) cases per 100 person-years; metformin reduced incidence by 31% vs placebo (95% CI 17-43%) | |
| Pioglitazone (Actos) | Approved | Small molecule | PPAR-gamma | not yet graded | No reviewed efficacy summary in this indication | |
| Pramlintide (Symlin) | ApprovedUS marketing discontinued | Peptide | Amylin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| SAR341402 | Approved | Peptide | Insulin receptor | Partial signal | NCT03211858: Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041) | |
| Saxagliptin (Onglyza) | ApprovedUS marketing discontinued | Small molecule | DPP-4 | Reliable signal | NCT00121667: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07) NCT00121641: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg — Baseline Mean: 7.91 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.43 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 5 mg — Baseline Mean: 7.98 Percentage of glycosylated hemoglobins (Standard Error 0.11); Adjusted Mean Change from Baseline: -0.46 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 10 mg — Baseline Mean: 7.85 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.54 Percentage of glycosylated hemoglobins (Standard Error 0.1) vs Placebo — Baseline Mean: 7.88 Percentage of glycosylated hemoglobins (Standard Error 0.1); Adjusted Mean Change from Baseline: 0.19 Percentage of glycosylated hemoglobins (Standard Error 0.1) | |
| Semaglutide (Ozempic) | Approved | Peptide | GLP-1 receptor | Reliable signal | NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003. NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9% | |
| Semaglutide (Rybelsus) | Approved | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sitagliptin (Januvia) | Approved | Small molecule | DPP-4 | Partial signal | NCT00086502: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03) NCT00087516: Change From Baseline in A1C at Week 24 (Weeks 0-24): Sitagliptin 100 mg -0.61 Percent (95% CI -0.74 to -0.49) | Sitagliptin 200 mg -0.76 Percent (95% CI -0.88 to -0.64) vs Placebo 0.18 Percent (95% CI 0.06 to 0.3) | |
| Tirzepatide (Mounjaro) | Approved | Peptide | GLP-1/GIP receptor (dual) | Partial signal | NCT04255433: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Tirzepatide (MTD) 801/6586 vs 1.5 mg Dulaglutide 862/6579 NCT05260021: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (Baseline, Week 30): Pooled Doses of Tirzepatide (5 mg, 10 mg) -2.03 percentage of HbA1c (Standard Error 0.165) | Placebo -0.23 percentage of HbA1c (Standard Error 0.229) | |
| Miglitol (Glyset) | US approval withdrawn | Small molecule | Alpha-glucosidase | Partial signal | No reviewed efficacy summary in this indication | |
| Repaglinide (Prandin / NovoNorm) | US approval withdrawn | Small molecule | SUR1 (short-acting) | Partial signal | No reviewed efficacy summary in this indication | |
| Albenatide | Phase 3 | Peptide | GLP-1 receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Aleniglipron | Phase 3 | Small molecule | GLP-1 receptor | Weak signal | NCT05762471: Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo | |
| Anagliptin (Suiny) | Phase 3 | Small molecule | DPP-4 | Partial signal | NCT01529528: HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo. NCT01529541: Change in HbA1c from baseline to week 24: anagliptin (CWP-0403) -0.85% vs sitagliptin -0.83%; mean difference -0.02% (95% CI -0.22 to 0.18%); non-inferiority established. | |
| ASC30 | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Berberine Ursodeoxycholate (HTD1801) | Phase 3 | Small molecule | AMPK pathway / NLRP3 inflammasome (dual) | Reliable signal | NCT06350890: SYMPHONY 1 (NCT06350890, n=408): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.3%, statistically superior to placebo NCT06353347: SYMPHONY 2 (NCT06353347, n=551): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.2%, statistically superior to placebo | |
| Berobenatide | Phase 3 | Peptide | GLP-1 receptor | Partial signal | NCT06897202: Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose | |
| BGM0504 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Bofanglutide | Phase 3 | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Cagrilintide | Phase 3 | Peptide | Amylin receptor, Amylin/calcitonin receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Cagrilintide / Semaglutide (CagriSema) | Phase 3 | Peptide | Amylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual) | Reliable signal | NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001) NCT06534411: Primary endpoints: CagriSema 1.0 mg/1.0 mg superior to tirzepatide 5 mg for weight loss at week 60 (12.4% vs 9.1%) and non-inferior for HbA1c reduction (1.71% vs 1.67%) (2026-09-21). | |
| Chiglitazar (Bilessglu) | Phase 3 | Small molecule | PPAR (pan-agonist) | Reliable signal | NCT04807348: RECAM study, n=533 (178/177/178). LS mean change in HbA1c from baseline at Week 24: -0.91% (32mg), -1.14% (48mg), -0.49% (placebo); both doses vs placebo p<0.001; 48mg vs 32mg p=0.008. NCT02173457: CMAS trial, primary endpoint HbA1c change from baseline at week 24: chiglitazar 32mg and 48mg both non-inferior to sitagliptin 100mg, with treatment differences of -0.04% (95% CI -0.22 to 0.15) and -0.08% (95% CI -0.27 to 0.10) vs sitagliptin (arm sizes n=245/246/248, total 739, matching this trial's design and enrollment of 740) | |
| Cofrogliptin | Phase 3 | Small molecule | DPP-4 | Reliable signal | NCT04564872: HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin NCT04556851: HbA1c change from baseline to week 24, LS mean difference vs placebo: cofrogliptin (HSK7653) 10 mg -0.63% (95% CI: -0.81, -0.46); 25 mg -0.59% (95% CI: -0.77, -0.42); both p < 0.0001 | |
| Dapagliflozin / Linagliptin (Dapalina) | Phase 3 | Small molecule | SGLT2;DPP-4 | Partial signal | NCT06329674: Change in HbA1c at Week 24: -0.77% AJU-A51 vs +0.10% linagliptin+placebo; LS mean difference -0.88% (95% CI -1.07, -0.68), p<0.0001 | |
| Dorzagliatin (Huatangning) | Phase 3 | Small molecule | Glucokinase | Partial signal | NCT04531631: Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). missed | |
| Ecnoglutide | Phase 3 | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Efmedaglutide Alfa (Shanmeining) | Phase 3 | Protein / enzyme therapeutic | GLP-1 receptor | Partial signal | NCT06235086: Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30). | |
| Efpeglenatide | Phase 3 | Peptide | GLP-1 receptor | Partial signal | NCT03353350: Change in HbA1c from baseline to week 30 vs placebo: efpeglenatide 2 mg -0.5% (95% CI -0.9 to -0.2), p=0.0054; 4 mg -0.8% (-1.2 to -0.5), p<0.0001; 6 mg -1.0% (-1.4 to -0.7), p<0.0001 (AMPLITUDE-M, Rosenstock 2022, Diabetes Care). | |
| Efsubaglutide Alfa | Phase 3 | Protein / enzyme therapeutic | GLP-1 receptor | Reliable signal | NCT04994288: HbA1c change from baseline at week 24 (SUPER-1, phase III stage): 1 mg dose -1.73% (95% CI -20.98,-16.83 mmol/mol), 3 mg dose -2.15% (95% CI -25.68,-21.31 mmol/mol); estimated treatment difference vs placebo -1.26% (1 mg, 95% CI -17.39,-10.06 mmol/mol) and -1.68% (3 mg, 95% CI -22.08,-14.64 mmol/mol), both CIs excluding zero. NCT04998032: HbA1c change from baseline at week 24 (SUPER-2, add-on to metformin): Efsubaglutide 3 mg -1.80% vs placebo -0.74%; estimated treatment difference -1.06% (p<0.001) | |
| Elecoglipron | Phase 3 | Small molecule | GLP-1 receptor | Reliable signal | NCT06579105: HbA1c reduction over 26 weeks: 1.9% with elecoglipron 75 mg (highest dose) vs 0.2% with placebo | |
| Enavogliflozin (Envlo) | Phase 3 | Small molecule | SGLT2 | Reliable signal | NCT04634500: Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35% NCT04632862: Placebo-adjusted mean change in HbA1c from baseline at week 24 in the enavogliflozin 0.3 mg group: -0.99% (95% confidence interval -1.24%, -0.74%). | |
| Enicepatide | Phase 3 | Peptide | GLP-1 receptor, GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Evogliptin (Suganon) | Phase 3 | Small molecule | DPP-4 | Reliable signal | NCT04170998: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001) NCT02949193: HbA1c change from baseline at 24 weeks: -0.59% with evogliptin 5mg (n=112) vs -0.65% with sitagliptin 100mg (n=110), both add-on to metformin; between-group difference 0.06 percentage points (95% CI -0.10 to 0.22), demonstrating non-inferiority. | |
| Exendin-4 Fc Fusion (JY09) | Phase 3 | Protein / enzyme therapeutic | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Gemigliptin (Zemiglo) | Phase 3 | Small molecule | DPP-4 | Reliable signal | NCT03842267: LSM difference in HbA1c change at week 24 (gemigliptin add-on vs placebo, on background dapagliflozin + metformin): −0.66% (SE 0.07), 95% CI −0.80% to −0.52%. NCT02831361: Change in HbA1c from baseline at Week 24, between-group mean difference (gemigliptin 50 mg vs placebo, added to insulin ± metformin): -0.7 percentage points (95% CI -0.9 to -0.4), p<0.0001 | |
| Gosogliptin | Phase 3 | Small molecule | DPP-4 | Partial signal | NCT03088670: Primary, HbA1c change at week 12 (monotherapy stage): 8.61% to 7.41% with gosogliptin vs 8.7% to 7.34% with vildagliptin (each p<0.05 vs baseline); the between-group difference was not significant and no non-inferiority test or margin is reported. Week 36 not reported. Target HbA1c <=7.0%: 41% vs 44% (p=0.53). | |
| GZR33 | Phase 3 | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| HDG1901 | Phase 3 | Peptide | GLP-1 receptor | Partial signal | NCT06739044: HbA1c change from baseline to week 32 (equivalence, margin ±0.4%): HDG1901 -2.047% vs Ozempic -2.008%; treatment difference -0.038% (95% CI -0.189 to 0.112), within the margin, met. | |
| HDM1002 | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| HDM1005 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Henagliflozin | Phase 3 | Small molecule | Sodium-glucose cotransporter 2 (SGLT2) | Reliable signal | NCT04390295: Placebo-adjusted LS mean HbA1c change at Week 24: -0.76% (5 mg) and -0.80% (10 mg) vs placebo, both P < .0001. NCT03159052: Placebo-adjusted LS mean HbA1c change at Week 24: -0.91% (5 mg) and -0.94% (10 mg) vs placebo, both P < .001. | |
| HR17031 | Phase 3 | Peptide | Insulin receptor / GLP-1 receptor (combination) | Partial signal | NCT06881264: Week 26 HbA1c change, LS mean: HR17031 -1.85% vs insulin glargine -1.06% (sponsor-reported) NCT06871761: HbA1c change from baseline at week 26: HR17031 -1.53% vs insulin glargine -0.25%; LS-mean difference -1.29% (95% CI -1.48 to -1.10), P<0.0001 (sponsor-reported, ADA 2026) | |
| IcoSema (Kyinsu) | Phase 3 | Peptide | Insulin receptor (basal), GLP-1 receptor | Partial signal | NCT06269107: (-3·32 vs -2·44 percentage points; estimated treatment difference [ETD] -0·88 percentage points [95% CI -1·12 to -0·63]), confirming superiority of IcoSema (p<0·001) NCT05352815: Change in Glycated Haemoglobin (HbA1c) (Baseline (Week 0), Week 52): IcoSema -1.6 Percentage point of HbA1c (Standard Deviation 0.99) vs Insulin Icodec -0.9 Percentage point of HbA1c (Standard Deviation 1.01) | |
| Insulin Sudelidec (INS068) | Phase 3 | Peptide | Insulin receptor (basal) | Partial signal | NCT05699408: Change in HbA1c at Week 26 (Study 302, oral-antidiabetic-drug background, n=513): insulin sudelidec (INS068) -1.34% vs insulin glargine -1.37%; between-group difference 0.02% (95% CI -0.14% to 0.18%) NCT05702073: Change in HbA1c at Week 26 (Study 301, basal-insulin background, n=423): insulin sudelidec (INS068) -0.70% vs insulin glargine -0.83%; between-group difference 0.13% (95% CI -0.05% to 0.31%) | |
| Janagliflozin (Huiyoujing) | Phase 3 | Small molecule | SGLT2 | Reliable signal | NCT03811548: Placebo-adjusted HbA1c change at week 24: janagliflozin 25 mg -0.80% (95% CI -0.98 to -0.62), 50 mg -0.88% (95% CI -1.06 to -0.70); P<0.001 for both (Ji et al., Diabetes Obes Metab 2023) | |
| JW0201 | Phase 3 | Small molecule | Dipeptidyl peptidase-4 (DPP-4) | Partial signal | NCT05814393: HbA1c change from baseline at Week 24: -0.83% with JW0201 (anagliptin) add-on vs -0.03% with placebo; between-group difference -0.80 percentage points (95% CI -0.95 to -0.64; P<0.0001) | |
| Lobeglitazone (Duvie) | Phase 3 | Small molecule | PPAR-gamma | Weak signal | NCT03739125: HbA1c change at 24 weeks vs placebo (Study 1, empagliflozin 10 mg plus metformin background): -0.71% (95% CI -0.88 to -0.55), p<0.001. The publication reports Study 2 (empagliflozin 25 mg background, NCT03627182) separately. NCT01106131: HbA1c change at week 24: -0.74% lobeglitazone vs -0.74% pioglitazone (difference 0.01%, 95% CI -0.16 to 0.18); noninferior. | |
| Maridebart Cafraglutide (MariTide) | Phase 3 | Peptide | GLP-1R agonist; GIPR antagonist | Reliable signal | No reviewed efficacy summary in this indication | |
| Mazdutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | Reliable signal | NCT05606913: HbA1c change from baseline at Week 28: -1.61 percentage points (mazdutide 4mg) and -1.66 percentage points (mazdutide 6mg) vs -1.36 percentage points (dulaglutide 1.5mg); superiority P<.01 for both doses. NCT05628311: HbA1c change from baseline at week 24: -1.57% (mazdutide 4mg), -2.15% (mazdutide 6mg) vs -0.14% (placebo); mazdutide superior to placebo | |
| Mitiglinide (Glufast) | Phase 3 | Small molecule | SUR1 (short-acting) | Partial signal | NCT01037842: Change in HbA1c from randomization to Week 16 endpoint: metformin+mitiglinide -0.7% (SD 0.6) vs metformin+placebo -0.4% (SD 0.7); difference significant at P=0.002. NCT00461617: Change in HbA1c from baseline: mitiglinide -0.53% (wk12) / -0.77% (wk20) vs nateglinide -0.58% (wk12) / -0.71% (wk20); intergroup difference 0.05% (95% CI -0.19 to 0.30) at week 12 and 0.06% (95% CI -0.31 to 0.19) at week 20. | |
| Noiiglutide | Phase 3 | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Obicetrapib | Phase 3 | Small molecule | CETP | not yet graded | No reviewed efficacy summary in this indication | |
| Olatorepatide | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Pegloxenatide (Fulaimei) | Phase 3 | Peptide | GLP-1 receptor | Reliable signal | NCT02477969: Phase 3b add-on-to-metformin trial: proportion achieving HbA1c <7.0% at week 24 was 37.4% (100μg) and 40.6% (200μg) vs 16.8% (placebo). NCT02477865: Phase 3a monotherapy trial: HbA1c LS-mean change at week 24 was -1.02% (100μg) and -1.34% (200μg) vs -0.17% (placebo), p<0.0001. | |
| RAY1225 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Retatrutide | Phase 3 | Peptide | GLP-1/GIP/glucagon receptor (triple) | Partial signal | NCT05929079: Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract. NCT06354660: Change in HbA1c from baseline (7.9%) at Week 40: 4 mg -1.7%, 9 mg -2.0%, 12 mg -1.9%, placebo -0.8%; retatrutide met the primary endpoint. | |
| Ribupatide | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | Partial signal | NCT06650007: Change in HbA1c from baseline (efficacy estimand): maximum mean reduction of 2.67% with once-weekly ribupatide injection (4 mg and 2 mg) vs placebo NCT06649344: Primary, HbA1c change from baseline to week 36 (non-inferiority vs semaglutide 1 mg, efficacy estimand): ribupatide 4 mg -2.78%, 2 mg -2.34%, semaglutide -2.29%; non-inferiority achieved for both doses (margin and CI not published), and 4 mg statistically superior to semaglutide, met. | |
| Safiglipron (HRS-7535) | Phase 3 | Small molecule | GLP-1 receptor | Partial signal | NCT06589765: Primary, HbA1c change from baseline at week 32 vs dapagliflozin 10 mg (non-inferiority margin 0.4%, primary non-inferiority estimand): 30 mg -0.30% (95% CI -0.51 to -0.09), 60 mg -0.22% (95% CI -0.44 to -0.01), 90 mg -0.40% (95% CI -0.62 to -0.19); non-inferiority met for all three doses (all P<0.0001). Superiority (treatment policy estimand): 90 mg -0.25% (95% CI -0.45 to -0.05; one-sided P=0.0067), 60 mg not significant (P=0.0789). NCT06672172: OUTSTAND-1 phase 3 T2D trial (placebo-controlled, diet-and-exercise inadequately controlled); enrollment (284) matches this listing exactly. Primary endpoint (HbA1c reduction at Week 32 vs placebo, across 30/60/90mg doses) was met: 1.40-1.68% reduction vs 0.06% for placebo. | |
| Survodutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | Partial signal | NCT06066528: Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-2, primary analysis, treatment-regimen estimand): -9.8% survodutide 6.0 mg and -8.2% 3.6 mg vs -3.9% placebo; body weight reduction of at least 5%: 64.5% and 57.6% vs 35.1% (P<0.001 for all comparisons with placebo). | |
| UBT251 | Phase 3 | Peptide | GLP-1/GIP/glucagon receptor (triple) | not yet graded | No reviewed efficacy summary in this indication | |
| Vicadrostat | Phase 3 | Small molecule | Aldosterone synthase (CYP11B2) | not yet graded | No reviewed efficacy summary in this indication | |
| Visepegenatide (PB-119) | Phase 3 | Peptide | GLP-1 receptor | Reliable signal | NCT04504396: Change in HbA1c from baseline: -1.25% (95% CI -1.35 to -1.16) with visepegenatide (PB-119) vs -0.68% (95% CI -0.78 to -0.59) with placebo; treatment difference -0.57% (95% CI -0.71 to -0.43), p<0.001. NCT04504370: LSM change in HbA1c from baseline to week 24: visepegenatide (PB-119) -1.36% (95% CI -1.52 to -1.20) vs placebo -0.63% (95% CI -0.79 to -0.46); treatment difference -0.73% (95% CI -0.96 to -0.50, p<0.001) | |
| VK2735 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Zenagamtide | Phase 3 | Peptide | GLP-1/amylin receptor (dual) | Partial signal | NCT06542874: HbA1c change from baseline to week 36: up to -1.8% (once-weekly subcutaneous) and up to -1.5% (once-daily oral); statistically significant vs placebo, primary endpoints confirmed | |
| DA-302168S | Phase 2 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Exenatide (PT320) | Phase 2(overall) | Peptide | GLP-1 receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| HM15275 | Phase 2 | Peptide | GLP-1/GIP/glucagon receptor (triple) | not yet graded | No reviewed efficacy summary in this indication | |
| NNC0519-0130 | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | Weak signal | No reviewed efficacy summary in this indication | |
| NNC0662-0419 | Phase 2 | Peptide | GLP-1 / GIP / Amylin receptors | not yet graded | No reviewed efficacy summary in this indication | |
| PG-102 | Phase 2 | Protein / enzyme therapeutic | GLP-1/GLP-2 receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Regor GLP-1 | Phase 2 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| SAL0150 | Phase 2 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Tifeglipron | Phase 2 | Small molecule | GLP-1 receptor | Weak signal | No reviewed efficacy summary in this indication | |
| TTP273 | Phase 2 | Small molecule | GLP-1 receptor | Reliable signal | NCT02653599: Change in HbA1c from baseline at Week 12: placebo-subtracted difference -0.86 percentage points (TTP273 150 mg once daily) and -0.71 percentage points (TTP273 150 mg twice daily); placebo arm HbA1c increased 0.15 percentage points from baseline; described as a statistically significant reduction. | |
| Utreglutide | Phase 2 | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| VCT220 | Phase 2 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| XW014 | Phase 1 | Small molecule | GLP-1 receptor | Weak signal | No reviewed efficacy summary in this indication | |
| MGL-2086 | —(overall) | Small molecule | GLP-1 receptor | not yet graded(overall) | No reviewed efficacy summary in this indication |
Large race: only the 107 furthest-along competitors are listed; 45 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
42 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(18 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Foundayo (orforglipron) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (9)
February 2027 (1)
May 2027 (1)
What to watch
August 2027 (3)
What to watch
What to watch
What to watch
September 2027 (3)
What to watch
What to watch
What to watch
December 2027 (1)
2028 (4)
2029 (2)
2030 (1)
March 2030 (1)
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent